Literature DB >> 26340605

Neuropathology of α-synuclein propagation and braak hypothesis.

Heather McCann1, Heidi Cartwright1, Glenda M Halliday1,2.   

Abstract

Parkinson's disease is a progressive neurodegenerative disorder with multiple factors contributing to increasing severity of pathology in specific brain regions. The Braak hypothesis of Lewy pathology progression in Parkinson's disease proposes a systematic spread of α-synuclein that can be staged, with the later stages correlating with clinical aspects of the disease. The spread of pathology through the different stages suggests progression, a theory that has proven correct from evidence of pathology in healthy neurons grafted into the brains of patients with Parkinson's disease. Progression of pathology occurs on a number of levels, within a cell, between nearby cells, and then over longer distances throughout the brain, and evidence using prion proteins suggests two dissociable mechanisms-intracellular toxicity versus a nontoxic infectious mechanism for propagation. In Parkinson's disease, intracellular changes associated with mitochondria and lysosome dysfunction appear important for α-synuclein propagation, with high stress conditions favoring mitochondrial cell death mechanisms. Functional neurons appear necessary for propagation. Unconventional exocytosis releases α-synuclein under stress conditions, and endocytic uptake occurs in nearby cells. This cell-to-cell transmission of α-synuclein has been recapitulated in both cell culture and animal models, but the timeframe of transmission is considerably shorter than that observed in transplanted neurons. The time course of Lewy pathology formation in patients is consistent with the long time course observed in grafted neurons, and the restricted neuronal loss in Parkinson's disease is potentially important for the propagation of α-synuclein through relatively intact circuits.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Lewy bodies; disease progression; propagation; α-synuclein

Mesh:

Substances:

Year:  2015        PMID: 26340605     DOI: 10.1002/mds.26421

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  37 in total

Review 1.  The c-Abl inhibitor in Parkinson disease.

Authors:  Zhi-Hua Zhou; Yun-Fan Wu; Xue-Min Wang; Yong-Zhu Han
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

2.  Natural history of pure autonomic failure: A United States prospective cohort.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma; Italo Biaggioni; Phillip A Low; Wolfgang Singer; David S Goldstein; Amanda C Peltier; Cyndia A Shibao; Christopher H Gibbons; Roy Freeman; David Robertson
Journal:  Ann Neurol       Date:  2017-02       Impact factor: 10.422

Review 3.  Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-11-01       Impact factor: 10.005

Review 4.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

5.  Structural and Functional Network Dysfunction in Parkinson Disease.

Authors:  Todd M Herrington; Jessica Briscoe; Emad Eskandar
Journal:  Radiology       Date:  2017-12       Impact factor: 11.105

6.  Exosomes from patients with Parkinson's disease are pathological in mice.

Authors:  Chao Han; Nian Xiong; Xingfang Guo; Jinsha Huang; Kai Ma; Ling Liu; Yun Xia; Yan Shen; Jie Li; Haiyang Jiang; Luxi Wang; Shiyi Guo; Xiaoyun Xu; Guoxin Zhang; Jingyu Liu; Xuebing Cao; Zhentao Zhang; Zhicheng Lin; Tao Wang
Journal:  J Mol Med (Berl)       Date:  2019-07-13       Impact factor: 4.599

Review 7.  Gastrointestinal dysfunction in movement disorders.

Authors:  Ryuji Sakakibara
Journal:  Neurol Sci       Date:  2021-02-04       Impact factor: 3.307

8.  Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.

Authors:  David S Goldstein; Yunden Jinsmaa; Patti Sullivan; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

9.  Multiple system atrophy-associated oligodendroglial protein p25α stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential.

Authors:  Nelson Ferreira; Hjalte Gram; Zachary A Sorrentino; Emil Gregersen; Sissel Ida Schmidt; Lasse Reimer; Cristine Betzer; Clara Perez-Gozalbo; Marjo Beltoja; Madhu Nagaraj; Jie Wang; Jan S Nowak; Mingdong Dong; Katarina Willén; Ersoy Cholak; Kaare Bjerregaard-Andersen; Nicolas Mendez; Prakruti Rabadia; Mohammad Shahnawaz; Claudio Soto; Daniel E Otzen; Ümit Akbey; Morten Meyer; Benoit I Giasson; Marina Romero-Ramos; Poul Henning Jensen
Journal:  Acta Neuropathol       Date:  2021-05-12       Impact factor: 17.088

Review 10.  Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.